Clinical trial
Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in…
NCT00439634 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT00439634 |
|---|---|
| Title | Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia |
| Official title | A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of 3 Oral Doses of AVE1625 and Placebo on Top of Either Olanzapine, Risperidone/Paliperidone, Quetiapine or Aripiprazole in the Treatment of Cognitive Impairment in Schizophrenia. |
| Acronym | CONNECT |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | AVE1625, placebo |
| Enrollment | 873 |
| Start date | Feb 1, 2007 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Feb 23, 2007 |
| Last update posted | May 18, 2016 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: